GlassScriptPhysician profile
Prakash Acharya
NPI 1912306895
$6,530.66
in general payments reported to CMS, 2019-2025
19 companies · $978 in 2025
The $978 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $334 · 2021: $557 · 2022: $378 · 2023: $3,196 · 2024: $924 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,071 · Travel and Lodging: $1,965 · Education: $62.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,070.55 |
| Travel and Lodging | $1,964.83 |
| Education | $62.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,560.04 | 2019-2024 | Supera, Coroflow, Xience Skypoint |
| Medtronic, INC. | $631.07 | 2022-2025 | Resolute Onyx, Aurora Ev-Icd Mri Surescan |
| Teleflex LLC | $488.55 | 2025 | Guideliner |
| Biotronik INC. | $417.05 | 2023-2024 | Biomonitor, Rivacor 7 Dr-T, Recross |
| Boston Scientific Corporation | $345.74 | 2023-2025 | Avvigo Guidance System, Watchman Access System |
| Medtronic Vascular, INC. | $200.00 | 2020 | |
| Abiomed | $196.18 | 2023-2025 | Impella |
| Amgen INC. | $180.84 | 2020-2025 | Repatha, Repatha |
| Shockwave Medical, INC | $81.59 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $78.55 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $75.55 | 2024-2025 | Eliquis, Camzyos |
| Chiesi USA, INC. | $62.01 | 2024 | Kengreal |
| Astrazeneca Pharmaceuticals LP | $58.43 | 2024-2025 | Wainua, Farxiga |
| Janssen Pharmaceuticals, INC | $40.74 | 2024 | Xarelto |
| Scpharmaceuticals INC. | $29.07 | 2024-2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $27.33 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.91 | 2025 | Jardiance |
| Philips North America LLC | $19.05 | 2024 | (Bs1) Peripheral Vascular Undivided |
| Novo Nordisk INC | $16.96 | 2024 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prakash Acharya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.